Location Matters: Mitochondrial Arginase 2 as a Treatment for Metabolic Disease?
Open Access
- 10 March 2024
- journal article
- editorial
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 17 (5) , 883-884
Abstract
No abstract availableFunding Information
- NIH
- CHEO Research Institute
- National Institutes of Health (R01DK125497, T32DK007314)
This publication has 12 references indexed in Scilit:
- A Structure-function Analysis of Hepatocyte Arginase 2 Reveals Mitochondrial Ureahydrolysis as a Determinant of Glucose OxidationCellular and Molecular Gastroenterology and Hepatology, 2024
- Mitochondrial arginase-2 is essential for IL-10 metabolic reprogramming of inflammatory macrophagesNature Communications, 2021
- Hepatic arginase 2 (Arg2) is sufficient to convey the therapeutic metabolic effects of fastingNature Communications, 2019
- Association between insulin resistance and the development of cardiovascular diseaseCardiovascular Diabetology, 2018
- Mutations and common variants in the human arginase 1 (ARG1) gene: Impact on patients, diagnostics, and protein structure considerationsHuman Mutation, 2018
- Prevalence, Metabolic Features, and Prognosis of Metabolically Healthy Obese Italian IndividualsDiabetes Care, 2010
- Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcriptionProceedings of the National Academy of Sciences, 2004
- Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individualsMetabolism, 2004
- Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR).Journal of Clinical Investigation, 1997
- Human type II arginase: sequence analysis and tissue-specific expressionGene, 1997